Artia Global Partners LP is an SEC-registered investment adviser based in Miami, FL that reports managing 1 hedge fund on Form ADV. It reports $778.9 million in regulatory assets under management. Its private funds, of all types, hold $778.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +3.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +13.7% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $778.9 millionForm ADV Item 5.F
- Gross assets of private funds
- $778.9 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 5Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 322091
- Latest Form ADV
- 03/31/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +8.8% | +14.8% |
| Q1 2026 | -4.7% | -4.6% |
| Q4 2025 | +0.6% | +2.4% |
| Q3 2025 | +20.0% | +7.8% |
| Q2 2025 | +7.1% | +10.4% |
| Q1 2025 | +3.3% | -4.5% |
| Q4 2024 | -16.5% | +2.1% |
| Q3 2024 | -1.7% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 50 share positions ($491,788,717) reported by Artia Global Partners LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Insmed Inc13.67%
- Revolution Medicines Inc7.74%
- Abivax SA7.33%
- Brightspring Health Svcs Inc7.04%
- Trevi Therapeutics Inc6.44%
- Argenx SE5.80%
- Travere Therapeutics Inc4.77%
- Alkermes PLC3.70%
- Guardant Health Inc3.51%
- Astrazeneca PLC3.23%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Insmed Inc | $67,234,395 | 13.67% | 589,052 | Unchanged |
| Revolution Medicines Inc | $38,053,151 | 7.74% | 185,390 | Unchanged |
| Abivax SA | $36,069,817 | 7.33% | 364,268 | -29.47% |
| Brightspring Health Svcs Inc | $34,614,322 | 7.04% | 609,944 | +17.91% |
| Trevi Therapeutics Inc | $31,659,401 | 6.44% | 2,210,852 | Unchanged |
| Argenx SE | $28,517,024 | 5.80% | 29,739 | Unchanged |
| Travere Therapeutics Inc | $23,463,268 | 4.77% | 398,493 | +17.54% |
| Alkermes PLC | $18,192,021 | 3.70% | 448,964 | Unchanged |
| Guardant Health Inc | $17,248,125 | 3.51% | 96,704 | +153.82% |
| Astrazeneca PLC | $15,884,773 | 3.23% | 98,376 | Unchanged |
| Quest Diagnostics Inc | $15,177,985 | 3.09% | 65,122 | Unchanged |
| Dianthus Therapeutics Inc | $14,592,967 | 2.97% | 165,735 | +1.68% |
| Revvity Inc | $12,376,140 | 2.52% | 80,948 | New |
| Newamsterdam Pharma Company | $12,255,724 | 2.49% | 503,936 | Unchanged |
| Merck & Co Inc | $11,697,455 | 2.38% | 80,500 | +72.38% |
| Johnson & Johnson | $7,174,454 | 1.46% | 27,100 | +19.91% |
| Bruker Corp | $6,720,791 | 1.37% | 103,796 | New |
| Biogen Inc | $6,604,054 | 1.34% | 29,237 | +58.58% |
| Edgewise Therapeutics Inc | $6,543,705 | 1.33% | 161,175 | +63.13% |
| Viking Therapeutics Inc | $5,891,831 | 1.20% | 180,731 | Unchanged |
| Rapport Therapeutics Inc | $5,594,669 | 1.14% | 166,508 | +20.22% |
| Thermo Fisher Scientific Inc | $5,137,131 | 1.04% | 7,610 | New |
| Absci Corporation | $5,002,062 | 1.02% | 464,444 | Unchanged |
| Roivant Sciences LTD | $4,746,786 | 0.97% | 129,800 | Unchanged |
| Cytokinetics Inc | $4,659,837 | 0.95% | 70,700 | Unchanged |
| Scholar Rock Hldg Corp | $4,652,491 | 0.95% | 96,285 | Unchanged |
| Belite Bio Inc | $4,243,632 | 0.86% | 24,989 | Unchanged |
| 10X Genomics Inc | $4,183,668 | 0.85% | 46,300 | New |
| Ascendis Pharma A/s | $4,041,704 | 0.82% | 17,740 | Unchanged |
| Celcuity Inc | $4,017,509 | 0.82% | 50,522 | -14.83% |
| Grail Inc | $3,531,024 | 0.72% | 25,200 | New |
| Mineralys Therapeutics Inc | $3,462,914 | 0.70% | 137,800 | Unchanged |
| Enliven Therapeutics Inc | $3,305,064 | 0.67% | 72,100 | Unchanged |
| Protagonist Therapeutics Inc | $3,233,566 | 0.66% | 22,951 | Unchanged |
| Twist Bioscience Corp | $2,956,572 | 0.60% | 15,300 | New |
| Oruka Therapeutics Inc | $2,781,886 | 0.57% | 33,400 | Unchanged |
| United Therapeutics Corp Del | $2,709,450 | 0.55% | 5,000 | Unchanged |
| Kiniksa Pharmaceuticals Intl | $2,178,612 | 0.44% | 29,200 | Unchanged |
| Corcept Therapeutics Inc | $2,074,140 | 0.42% | 18,000 | New |
| Bright Minds Biosciences Inc | $1,913,437 | 0.39% | 38,407 | Unchanged |
| Eyepoint Inc | $1,519,562 | 0.31% | 464,698 | -39.42% |
| Recursion Pharmaceuticals In | $1,381,080 | 0.28% | 334,402 | New |
| Agilent Technologies Inc | $999,398 | 0.20% | 5,800 | New |
| Prokidney Corp | $919,215 | 0.19% | 553,744 | -69.35% |
| Praxis Precision Medicines I | $728,075 | 0.15% | 2,500 | Unchanged |
| Pepgen Inc | $496,884 | 0.10% | 205,324 | Unchanged |
| MBX Biosciences Inc | $486,546 | 0.10% | 8,300 | New |
| Spyre Therapeutics Inc | $356,120 | 0.07% | 4,000 | Unchanged |
| Ginkgo Bioworks Holdings Inc | $262,297 | 0.05% | 20,444 | New |
| Climb Bio Inc | $241,983 | 0.05% | 21,097 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 12 new positions, 9 sold out, 9 increased, 4 reduced and 25 unchanged.
Number of positions (a count, not dollars)
- New positions12
- Increased9
- Unchanged25
- Reduced4
- Sold out9
New positions
| Stock | Value | Shares |
|---|---|---|
| Revvity Inc | $12,376,140 | 80,948 |
| Bruker Corp | $6,720,791 | 103,796 |
| Thermo Fisher Scientific Inc | $5,137,131 | 7,610 |
| 10X Genomics Inc | $4,183,668 | 46,300 |
| Grail Inc | $3,531,024 | 25,200 |
| Twist Bioscience Corp | $2,956,572 | 15,300 |
| Corcept Therapeutics Inc | $2,074,140 | 18,000 |
| Recursion Pharmaceuticals In | $1,381,080 | 334,402 |
| Agilent Technologies Inc | $999,398 | 5,800 |
| MBX Biosciences Inc | $486,546 | 8,300 |
| Ginkgo Bioworks Holdings Inc | $262,297 | 20,444 |
| Climb Bio Inc | $241,983 | 21,097 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Ionis Pharmaceuticals Inc | $11,447,573 | 144,376 |
| Alumis Inc | $7,838,284 | 278,546 |
| Sionna Therapeutics Inc | $5,267,407 | 119,741 |
| Palisade Bio Inc | $4,164,047 | 1,992,367 |
| Xenon Pharmaceuticals Inc | $3,923,400 | 65,000 |
| Compass Therapeutics Inc | $839,208 | 383,200 |
| Kodiak Sciences Inc | $663,060 | 17,019 |
| Tenax Therapeutics Inc | $612,264 | 42,080 |
| Nuvalent Inc | $605,150 | 4,900 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Guardant Health Inc | +58,604 | +153.82% | $17,248,125 | 96,704 |
| Brightspring Health Svcs Inc | +92,629 | +17.91% | $34,614,322 | 609,944 |
| Merck & Co Inc | +33,800 | +72.38% | $11,697,455 | 80,500 |
| Travere Therapeutics Inc | +59,460 | +17.54% | $23,463,268 | 398,493 |
| Edgewise Therapeutics Inc | +62,375 | +63.13% | $6,543,705 | 161,175 |
| Biogen Inc | +10,800 | +58.58% | $6,604,054 | 29,237 |
| Johnson & Johnson | +4,500 | +19.91% | $7,174,454 | 27,100 |
| Rapport Therapeutics Inc | +28,000 | +20.22% | $5,594,669 | 166,508 |
| Dianthus Therapeutics Inc | +2,745 | +1.68% | $14,592,967 | 165,735 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Abivax SA | -152,179 | -29.47% | $36,069,817 | 364,268 |
| Prokidney Corp | -1,253,195 | -69.35% | $919,215 | 553,744 |
| Eyepoint Inc | -302,400 | -39.42% | $1,519,562 | 464,698 |
| Celcuity Inc | -8,794 | -14.83% | $4,017,509 | 50,522 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (1)
As reported in the adviser's Form ADV filed Mar 26, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures